These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 16048941)

  • 1. Efficacy of cefepime and imipenem in experimental murine pneumonia caused by porin-deficient Klebsiella pneumoniae producing CMY-2 beta-Lactamase.
    Pichardo C; Rodríguez-Martínez JM; Pachón-Ibañez ME; Conejo C; Ibáñez-Martínez J; Martínez-Martínez L; Pachón J; Pascual A
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3311-6. PubMed ID: 16048941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
    Pichardo C; del Carmen Conejo M; Bernabéu-Wittel M; Pascual A; Jiménez-Mejías ME; de Cueto M; Pachón-Ibáñez ME; García I; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2005 Jan; 11(1):31-8. PubMed ID: 15649301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of porins and plasmid-mediated AmpC beta-lactamases on the efficacy of beta-lactams in rat pneumonia caused by Klebsiella pneumoniae.
    Padilla E; Alonso D; Doménech-Sánchez A; Gomez C; Pérez JL; Albertí S; Borrell N
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2258-60. PubMed ID: 16723600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase.
    Kang CI; Pai H; Kim SH; Kim HB; Kim EC; Oh MD; Choe KW
    J Antimicrob Chemother; 2004 Dec; 54(6):1130-3. PubMed ID: 15486080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of amikacin and imipenem alone and in combination against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.
    Máthé A; Szabó D; Anderlik P; Rozgonyi F; Nagy K
    Diagn Microbiol Infect Dis; 2007 May; 58(1):105-10. PubMed ID: 17300908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Cha R
    Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.
    Szabó D; Máthé A; Filetóth Z; Anderlik P; Rókusz L; Rozgonyi F
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1287-91. PubMed ID: 11257049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative activity of ertapenem against extended-spectrum beta-lactamase-producing or plasmid-mediated AmpC beta-lactamase-producing Klebsiella pneumoniae].
    Hernández JR; Conejo Mdel C; Pascual A
    Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):27-30. PubMed ID: 19631421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1.
    Rodríguez-Martínez JM; Pichardo C; García I; Pachón-Ibañez ME; Docobo-Pérez F; Pascual A; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2008 Jul; 14(7):691-7. PubMed ID: 18558942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of porin loss on the activity of tigecycline against Klebsiella pneumoniae producing extended-spectrum beta-lactamases or plasmid-mediated AmpC-type beta-lactamases.
    Conejo MC; Hernández JR; Pascual A
    Diagn Microbiol Infect Dis; 2008 Jul; 61(3):343-5. PubMed ID: 18339509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of OmpK35, OmpK36 Porins, and Production of β-Lactamases on Imipenem Susceptibility in Klebsiella pneumoniae Clinical Isolates, Cairo, Egypt.
    Wassef M; Abdelhaleim M; AbdulRahman E; Ghaith D
    Microb Drug Resist; 2015 Dec; 21(6):577-80. PubMed ID: 25945596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effects of carbapenems on bacterial load and host immune response in a Klebsiella pneumoniae murine pneumonia model.
    Hilliard JJ; Melton JL; Hall L; Abbanat D; Fernandez J; Ward CK; Bunting RA; Barron A; Lynch AS; Flamm RK
    Antimicrob Agents Chemother; 2011 Feb; 55(2):836-44. PubMed ID: 21135187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
    Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
    J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
    Burgess DS; Hall RG
    Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia.
    Song W; Moland ES; Hanson ND; Lewis JS; Jorgensen JH; Thomson KS
    J Clin Microbiol; 2005 Sep; 43(9):4891-4. PubMed ID: 16145169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 beta-lactamases.
    Lee CH; Chu C; Liu JW; Chen YS; Chiu CJ; Su LH
    J Antimicrob Chemother; 2007 Aug; 60(2):410-3. PubMed ID: 17576696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and contributing factors of nonsusceptibility to imipenem or meropenem in extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Park YJ; Yu JK; Park KG; Park YG; Lee S; Kim SY; Jeong SH
    Diagn Microbiol Infect Dis; 2011 Sep; 71(1):87-9. PubMed ID: 21397426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Labombardi VJ; Rojtman A; Tran K
    Diagn Microbiol Infect Dis; 2006 Nov; 56(3):313-5. PubMed ID: 17084784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of doripenem and ertapenem against KPC-2-producing and non-KPC-producing Klebsiella pneumoniae with similar MICs.
    Hagihara M; Crandon JL; Urban C; Nicolau DP
    J Antimicrob Chemother; 2013 Jul; 68(7):1616-8. PubMed ID: 23475648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced imipenem susceptibility in Klebsiella pneumoniae clinical isolates with plasmid-mediated CMY-2 and DHA-1 beta-lactamases co-mediated by porin loss.
    Lee K; Yong D; Choi YS; Yum JH; Kim JM; Woodford N; Livermore DM; Chong Y
    Int J Antimicrob Agents; 2007 Feb; 29(2):201-6. PubMed ID: 17204406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.